BIA Start-up Festival

Wednesday 19 May 2021

The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. 

This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to learn from peers and established industry experts alike.

Attendees will enjoy a mix of informal group networking, as well as the opportunity to arrange 1-1 meetings with key experts in the field, and the event will close with a virtual drinks reception.

The event platform will open for networking on 10 May, to allow you to plan your time at the event and make the most of the networking opportunities available.

Please note: this event is limited to attendees from start-up companies, entrepreneurs in the life sciences, and invited industry experts. If you are interested in supporting this event please contact Jane Wall at jwall@bioindustry.org

Agenda

09:00   Networking / 1-1 meetings
10:20   BIA introduction 
10:30   Session 1 - What to look for in pre-seed funding

Learn about different alternatives for raising pre-seed funding, including grants, angel investment and charity investment.   
11:30   Networking / 1-1 meetings
12:15   Session 2 - The investor perspective: what we wish you knew

Hear the perspective from the other side of the table, and get advice on improving your approach from the investors.
13:15   Lunch break and 1-1 meetings
14:00   Session 3 - Building your team for success

You can't do everything yourself - find out how best to build and develop the team you need for your company's success.
15:00   Networking / 1-1 meetings
15:45   Session 4 - Founder stories: wins and lessons

Listen to the stories of established CEOs, and the lessons they've learned since launching their companies.

Virtual networking reception 

17:00   Keynote - Mark Kotter (bit.bio) in conversation with John Cumbers (synbiobeta)
How bit.bio managed to create tech that can reprogram human cells with consistency and scale and why that's such a huge deal for biotechs
17:15   Networking around virtual 'tables'
18:30    Event closes

Speakers

Session 1 - What to look for in pre-seed funding

Barbara Domayne-Hayman

Entrepreneur-in-residence, Francis Crick Institute; CBO, Autifony Therapeutics Ltd

Francis Crick Institute

Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech.

Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-residence, where amongst other things, she helps to run an accelerator called KQ Labs, which is focused on start-ups making use of data/AI applied to health. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee.

Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech.

Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.

Pam Garside

Partner

Newhealth

Pam Garside has her own management consultancy, Newhealth, specialising in organisational strategy and development in health care, and is a Fellow of the Judge Business School of the University of Cambridge. She advises new entrants to the UK health market including digital and start up companies and is an angel investor.

Pam founded and co-chairs The Cambridge Health Network, a membership group of senior players in UK health,both private and public sector. She sits on the Investment Committee of Cambridge Enterprise, the technology transfer company of the University of Cambridge and is a member of Cambridge Angels.She is a board member of Whizz-Kidz charity, ZPB Ltd and a senior adviser to Smith Square Partners. In 2016 Pam was named one of the 100 most influential leaders in Health Tech by Hot Topics.

Pam began her professional life in management in the NHS and subsequently spent many years studying and working internationally based in the USA. She holds a BSc from the University of Durham and a Masters Degree in Hospital and Health Care Administration from the University of Minnesota. She is an Adjunct Professor at Imperial College Business School.

Perry Guess

Head of Partnerships

Ixion

Perry is the Head of Partnerships for Ixion’s Innovation Division, a not-for-profit, owned by a major charity, that is uniquely positioned to sharing the risk of grant applications. He has over 25 years’ experience in the innovation space and is passionate about helping organisation achieve their innovation ambitions through identifying and accessing funding and finance. As a former government funder (NERC) and Director of an Innovate UK KTN (ESKTN, based out of the University of Oxford), he has extensive knowledge and a deep understanding of funding landscape and what funders look for. Perry enjoys nothing more than talking to ambitious organisations about their great ideas and helping them make a difference.

Clare Terlouw

Head of LifeArc Ventures

LifeArc

Clare is an experienced life sciences corporate finance and investment specialist, with significant expertise in growth funding for innovative life sciences companies in the private and public markets. Clare has been on the BIA board since January 2019 and is now seeking re-election. Clare joined LifeArc in July 2020 as Head of LifeArc Ventures, responsible for developing and implementing a strategy for LifeArc’s investments across the life sciences sector, enhancing LifeArc’s commitment to funding the translation of promising life sciences research. LifeArc’s strategic investments in innovation are a key component of its charitable model, supporting both the ability to create impact for the benefit of patients and aims to contribute to its long-term sustainability.
Clare was recently at FTSE250 listed healthcare investment company Syncona Investment Management, where she was Head of Corporate Development. She also has over 15 years’ experience in healthcare investment banking and was Managing Director and Co-Head of Healthcare and Life Sciences at Numis Securities, specialising in equity capital markets and M&A for London listed companies. Clare is also a Non-Executive Director at the Stevenage Bioscience Catalyst.
Clare has been an enthusiastic supporter of the life sciences sector and understands the opportunities and challenges that funding growing companies in the sector brings. She is currently a member of the BIA Audit Committee and intends to continue in that role.

Session 2 - The investor perspective: what we wish you knew

Mark Andrews

Managing Director

PharmaVentures

For over 25 years Mark has been active in the Life Science industry. After starting in academic research in Cambridge, Mark has gone on to build a career in Life science investment and M&A Advisory.

As an active Life Science investor Mark was active as a Principal at Inventages in both Switzerland & London as well as at the DEWB Venture Capital in Jena, Germany during which time he managed numerous investments and took positions on the boards or took up board observer rights on the vast majority. His experience spans across the investment cycle, from sourcing through investment negotiation, hands-on portfolio management driving towards exit negotiation.

Additionally Mark was a member of the Corporate Finance M&A Life Science sector team at BDO in London where he was a core member of the team and worked with clients especially in the out sourced pharma services and medical devices sectors. The appointment of Mark has enabled PharmaVentures to strengthen our cross-border M&A and fundraising capabilities.

Paul Ashley

Director, Data Science External Innovation

J&J Innovation

Paul Ashley is Director, Data Science External Innovation, and is located at the EMEA Innovation Centre in London, UK. In this role, he is responsible for the development and maintenence of Data Science relevant partnerships and business opportunities with biotech companies, venture capital, academic, and governmental institutions in Europe.

Prior to joining Johnson & Johnson Innovation he was Head of Licensing and Ventures at Oxford University Innovation and has previously worked in a business development role at AstraZeneca and as the CEO of a spinout company based on technology developed at the UK’s Defence Science Technology Laboratory.

He holds a PhD in behaviour and physiology and a BSc Hons in Zoology.

Elizabeth Klein

CEO and Founder

Klein-Edmonds Associates

Prior to founding her own consultancy, Elizabeth was an award-winning and highly-rated senior research analyst focused on the Life Sciences and IP Commercialisation sectors. Over 15 years at N+1 Singer, Teathers, Bridgewell, R.W. Baird and Dresdner Kleinwort Benson she developed an extensive network of client relationships and worked closely with a number of businesses in these sectors. She was the Starmine Healthcare Stockpicker of the Year in both 2006 and 2013, and was highly rated in the Extel survey over much of her career in investment banking.

In 2015, Elizabeth founded Klein-Edmonds Associates, advising organisations in the biotechnology sector on their engagement and interaction with investors. She has consulted with Bioscience Managers since June 2017. Other clients: The BioIndustry Association, Radnor Capital, and Biotech & Money, and small businesses (Angel to pre-IPO) on corporate and investment strategy. Elizabeth is also a Trustee at the Royal National Orthopaedic Hospital (at Stanmore) Charity.

Elizabeth has a 1st Class BSc in Applied Biology with Genetics from the University of Liverpool, an MBA from Imperial College Business School and an MA (Merit) in Medicine, Science & Society (History of Medicine) from Birkbeck, University of London.

Oliver Sexton

Investment Director

UK Innovation & Science Seed Fund

Oliver invests from UKI2S, an early stage seed/series A fund that backs companies developing complex science and engineering led solutions to global challenges. Specialising in life science investments Oliver joined UKI2S in 2014. He has therapeutic, med tech, agritech and industrial biotech companies in the portfolio.

Prior to joining UKI2S Oliver managed commercialisation of bioengineering and medical technologies at Imperial Innovations and worked at Ark Therapeutics as well as managing a team of biotech buy-side analysts.

Oliver sits on the board of Ikarovec and Gyreox as well as multiple board observer positions.

Session 3 - Building your team for success

Charlotte Casebourne

CEO

Theolytics

Charlotte believes in equitable access to effective therapies. She is the CEO and Co-founder of Theolytics, a pre-clinical biotechnology company harnessing viruses to combat disease and a Board Member of the UK Bioindustry Association.

Previously Co-Founder of New Medicine Partners, Charlotte has worked with organisations spanning three continents to translate novel life science technologies to the point of commercial viability; clients included government ministries, national funding bodies and world leading research institutes. Her personal interests have led her to take leadership roles within a number of organisations, including: as curator of the World Economic Forum Global Shapers network; Managing Director of HealthTech Women London; and HelloTomorrow’s London Chair for Healthcare and Medical Technologies.

Charlotte graduated as a University of Cambridge Bioscience Enterprise M.Phil Scholar and was a shortlisted finalist for Cambridge Entrepreneur of the Year. She was the youngest listed 2016 nominee for MT’s 35 under 35 Award.

Kevin Pojasek

CEO

Enara Bio

Kevin Pojasek is a Venture Partner at SV and President and CEO of Enara Bio, an SV portfolio company. He joined the SV Venture Partner Program in September 2018 and co-founded Catamaran, an SV portfolio company, where he still serves as Executive Chairman.

Prior to joining SV, Kevin was Chief Strategy and Business Officer and a member of the executive leadership team at Immunocore Ltd. In this role, he was responsible for shaping the company’s corporate, R&D and growth strategies, as well as for overseeing business development. Kevin was also co-head of the company’s Infectious Disease Unit and helped lead the Bill & Melinda Gates Foundation investment of up to $40 million. Prior to joining Immunocore, Kevin was President, Chief Executive Officer of Quartet Medicine, a company he co-founded in late 2013 while working as an Entrepreneur-in-Residence at Atlas Ventures.

Kevin was also the Chief Operating Officer of Annovation Biopharma, another Atlas Ventures-funded company, which was sold to the Medicines Company in January 2015. He has also held senior executive R&D and corporate development roles at several venture capital-backed companies, including Vice President of Corporate Development at Kala Pharmaceuticals (NASDAQ:KALA) and, earlier in his career, spent time as an investment associate at PureTech Health (LSE: PRTC) an early stage venture capital firm.

Nathalie Rowell

CEO and Founder

Virdis Group

Nathalie brings over 18 years of experience and credibility in hiring international talent for the life science industry. She continues to advise senior executives in many different cultures on how to shape their careers and their organizations. A solid track record of international success has given Nathalie a deep understanding of the life-sciences and a strong empathy with our clients. Her extensive industry knowledge and specialist insight is valued highly, enabling Virdis clients to benchmark realistically, evaluate carefully, and find exactly the right individuals to lead and develop their organisations.

Nathalie created Virdis in 2007 and, since then, has built both a strong team and a broad network of skilled people around the world. Her understanding of life science organisations and her extensive experience make her a credible and well-recognized recruitment partner.

Nathalie read Law at Paris Assas University and worked as lawyer in the field of intellectual property before becoming an entrepreneur and moving to international executive search.

Session 4 - Founder stories: wins and lessons

Olivia Cavlan

Head of Business & Operations

Alchemab

Olivia is a biotechnology executive and former academic clinician experienced in supporting international pharmaceutical, biotech and med tech companies across strategic, business and operational activities. Olivia heads up business at Alchemab Therapeutics, an advanced-analytics enabled therapeutics company which she helped to build from inception having been a Principal at SV Health Investors. Prior to that, she was a Partner at McKinsey where she led healthcare private equity and global R&D restructuring efforts, and a Partner at QuantumBlack, focused on advanced-analytics projects for pharmacos. Olivia is also a Non-Executive Director at the BIA and a member of the Cancer Research UK (CRUK) Seed investment committee. She's passionate about innovation and regularly advises start-ups on company creation and financing topics.

Antoine Espinet

CEO

MicrofluidX

Antoine is the founder of MicrofluidX, developing a break-through bioreactor for large-scale cell culture based on the microfluidic technology. He has experience in cell and gene therapy manufacturing and system development. Prior to this, he worked as a engagement manager at McKinsey, in Brussels and Sydney. He graduated in 2012 with PhD in Engineering from Cornell University, USA, as well as from Ecole Centrale Paris in 2009 with a Master in Engineering.

Caroline Godfrey

CEO and Founder

PepGen

Caroline Godfrey is Senior Vice President of Discovery. having She is a co-founder of PepGen and led the company as CEO from spinout, successfully raising seed funding of $4.5M and a Series A of $45M. Caroline has deep experience with PepGen’s enhanced delivery oligonucleotide therapeutics, having worked as a post-doctoral researcher developing this proprietary technology at the University of Oxford. Prior to this, Dr Godfrey worked in genetics in a the private and NHS settings, and received her PhD from University College London following research in the field of neuromuscular diseases.

Jolyon Martin

Head of Business Development and Co-Founder

PetMedix

Jolyon is co-founder and Head of Business Development at PetMedix, a Cambridge-based biopharmaceutical company developing antibody-based therapeutics for companion animals. PetMedix is based on Jolyon's PhD work in the laboratory of Prof Allan Bradley FRS, who is CSO and co-founder of both PetMedix and Kymab Ltd. At PetMedix, Jolyon is responsible for external partnerships and licensing, and led the work to secure their recent partnership deal with Boehringer Ingelheim. He also works alongside the CEO and executive team to shape commercial strategy and the company’s future direction.

Balancing his studies at the University of Cambridge with an interest in start-ups and entrepreneurship, Jolyon worked with the founding team of Simprints for a year and also for Horizon Discovery in both Boston, MA and Cambridge, UK. He was part of the first BIA PULSE Cohort, was named Cambridge Young Entrepreneur of the Year in 2017, and was a finalist in Onestart 2014. Jolyon is passionate about diversity and representation, and volunteers with the Beyond Equality Initiative - running workshops on tackling toxic masculinity in university sports teams.

Noor Shaker

Founder and CEO

Glamorous AI

Noor is a serial biotech entrepreneur with a track record of achievements in AI having held an Assistant Professorship from Aalborg University. Noor has published numerous papers in the field of artificial intelligence and its application to drug discovery and is an inventor on a handful of patents. She is passionate about data and AI and on a mission to cure disease with the power of human and machine learning. She is currently the CEO at GlamorousAI, a biotech company that pushes the boundaries to what is possible with AI to cure debilitating diseases. She is a recognised healthcare leader, MIT innovator under 35 and in BBC 100 women for 2019.

Networking keynote

John Cumbers

Founder

SynBioBeta

John Cumbers is the founder of SynBioBeta. John is passionate about education and on the use and adoption of biological technologies. He has received multiple awards and grants from NASA and the National Academy of Sciences for his work in the field. John has been involved in multiple startups such as those producing food for space, microbes to extract lunar and martian resources, and hoverboards! John is an active investor through the DCVC SynBioBeta Fund and his synthetic biology syndicate on AngelList. John received a PhD in Molecular Biology, Cell Biology, and Biochemistry from Brown University, a MSc in Bioinformatics from Edinburgh University and an undergraduate degree from the University of Hull in Computer Science with Information Engineering.

Mark Kotter

CEO and Founder

Bit Bio

Mark is a doctor, scientist, and entrepreneur dedicated to transitioning biology to engineering for the benefit of patients. Born in Canada, he studied medicine in Graz, earned his PhD in Cambridge, and trained as a neurosurgeon in Vienna, Toronto, and Cambridge, where he currently practises, treating patients with spinal cord injury.

He is CEO & founder of bit.bio, co-founder of Meatable, a cultured meat startup that uses bit.bio's opti-ox technology and co-founder and trustee of myelopathy.org, the first charity dedicated to a common yet often overseen condition causing a 'slow motion spinal cord injury'.

Mark is best known for discovering the importance of macrophages for brain regeneration, which led to the first regenerative medicine trial for degenerative cervical myelopathy, and for developing opti-ox, a gene targeting approach that enables faithful execution of genetic information in cells. Applied to cellular reprogramming, opti-ox demonstrated that robust activation of a new cell type program (encoded in transcription factors) is necessary and sufficient to deterministically induce a new cellular identity. These findings challenge the theory that cell reprogramming depends on stochastically determined permissive states and enable the production of any human cell within days at purities approaching 100%.

 

Experts

Attendees will have the opportunity to meet with key experts in the field, held as 1-1 meetings on the event platform, with dedicated time in the agenda for these to take place.

This is an absolutely fantastic opportunity to meet with experts in a wide variety of topics, such as IP, legal, tax/finance, regulatory, HR and recruitment, insurance, funding, accelerators, and more, as well as mentors who can guide you more generally through the industry

Experts include:

Mark Andrews

Managing Director

PharmaVentures

For over 25 years Mark has been active in the Life Science industry. After starting in academic research in Cambridge, Mark has gone on to build a career in Life science investment and M&A Advisory.

As an active Life Science investor Mark was active as a Principal at Inventages in both Switzerland & London as well as at the DEWB Venture Capital in Jena, Germany during which time he managed numerous investments and took positions on the boards or took up board observer rights on the vast majority. His experience spans across the investment cycle, from sourcing through investment negotiation, hands-on portfolio management driving towards exit negotiation.

Additionally Mark was a member of the Corporate Finance M&A Life Science sector team at BDO in London where he was a core member of the team and worked with clients especially in the out sourced pharma services and medical devices sectors. The appointment of Mark has enabled PharmaVentures to strengthen our cross-border M&A and fundraising capabilities.

Ursula Arndt

Scientist

Illumina Accelerator

"Ursula Arndt, Ph.D., is the Staff Scientist at Illumina Accelerator Cambridge. She was previously responsible for the Illumina Solutions Labs at the EMEA HQ (Cambridge), the ISO 13485 accredited laboratory supporting internal and customer facing activities.

Ursula earned a M.A. in Palaeogenetics from the Johannes Gutenberg-University in Mainz, Germany and a Ph.D in molecular Archaeology from Simon Fraser University in Vancouver, Canada."

Paul Ashley

Director, Data Science External Innovation

J&J Innovation

Paul Ashley is Director, Data Science External Innovation, and is located at the EMEA Innovation Centre in London, UK. In this role, he is responsible for the development and maintenence of Data Science relevant partnerships and business opportunities with biotech companies, venture capital, academic, and governmental institutions in Europe.

Prior to joining Johnson & Johnson Innovation he was Head of Licensing and Ventures at Oxford University Innovation and has previously worked in a business development role at AstraZeneca and as the CEO of a spinout company based on technology developed at the UK’s Defence Science Technology Laboratory.

He holds a PhD in behaviour and physiology and a BSc Hons in Zoology.

Steve Bates

Chief Executive Officer

BIA

Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.

Linda Bradley

Head of Business Development

LifeArc

Linda is Head of Business Development a LifeArc, following a >25 year career in business development at GlaxoSmithKline. She has experience leading deal teams in licensing, divesting, spinning out and establishing discovery, development and commercialization alliances in the pharma R&D environment dealing with platform technologies and R&D assets. At LifeArc she now leads a team sourcing, partnering and licensing innovation aiming to ultimately benefit patients. Her historic scientific background is in genetics.

Vanessa Carle

Associate

PharmaVentures

Vanessa joins PharmaVentures as an Associate, bringing experience from drug discovery R&D, technology commercialisation, and the start-up ecosystem. Prior to joining PharmaVentures, Vanessa worked at EPFL as a co-PI on a translational project, aiming to develop and commercialise a novel and safer anticoagulant therapy. At the same time, she was in charge of identifying out-licensing partners for two additional drug development projects from the academic group. Vanessa also has experience in mentoring early-stage healthcare spin-off projects, acquired while collaborating with accelerators like MassChallenge Switzerland and Bench2biz.

Vanessa holds a BSc in Biotechnology from the University of Pavia (Italy), an MSc in Pharmaceutical Biotechnology from the Martin Luther University Halle-Wittenberg (Germany) and a PhD in Chemical Biology from the Swiss Federal Institute of Technology Lausanne (EPFL, Switzerland).

George Caterer

Membership and Business Development Executive

BIA

George joined the BIA in March 2020, working to promote membership and increase engagement with our current members.

After completing an MSci in Zoology at University College London, George worked as an editor for a portfolio of journals within the Springer Nature Group, before moving on to become an Ecology Consultant. He is a passionate about conservation and wildlife having spent time volunteering at London Zoo and within the jungle of Guyana, South America.

Ross Cummings

Director (Patents)

Gill Jennings & Every

Ross' core practice is in drafting and prosecuting UK and European patent applications. Ross is known for his clear and accessible explanations of complex matters and has a strong track record of getting difficult cases granted at the European Patent Office. Ross also has a very high success rate with European oppositions and appeals, both defending and opposing.

Adrian Dawkes

Managing Director

PharmaVentures

Adrian is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian led multiple consultancy, licensing and M&A mandates. Notable deals include licensing transactions between MedGenesis and Pfizer, Esteve and Mundipharma, and M&A for a UK diagnostics business with Bruker and the sale of NanoSight to Spectris plc.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. He has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies. Adrian has over 30 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors.
Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

Barbara Domayne-Hayman

Entrepreneur-in-residence, Francis Crick Institute; CBO, Autifony Therapeutics Ltd

Francis Crick Institute

Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech.

Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-residence, where amongst other things, she helps to run an accelerator called KQ Labs, which is focused on start-ups making use of data/AI applied to health. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee.

Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech.

Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.

Christian Hill

CEO

MAP BioPharma

"Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland."

Brenna Howley

Trainee Patent Attorney

Gill Jennings & Every

Brenna is part of the Chemistry and Life Sciences group at Gill Jennings & Every and her work involves patent prosecution, drafting, and providing advice on patent portfolio strategy. She has a particular interest in contentious matters, especially oppositions before the European Patent Office.

John Jappy

Partner

Gill Jennings & Every

John has huge experience advising biotechnology and pharma companies on how to protect their innovations.

Grace Jennings

Associate Director, Head of MAP Online

MAP BioPharma

"Grace joined MAP BioPharma as the Head of MAP Online after working at NICE for nine years, most recently as a Senior Scientific Adviser in NICE Scientific Advice. She is passionate about making sure that MAP Online is as useful a resource as possible for members, in order to support the development of and improving patient access to exciting new technologies.

Grace has significant experience of helping both pharma companies and medtech companies, as she was the co-developer of the award-winning META (Medtech Early Technical Assessment) tool. She led on the educational programme in NICE Scientific Advice, including the LSE-NICE joint Executive Master’s degree. She also contributed to the Models for the evaluation and purchase of antimicrobials project in collaboration with NHSE.

Grace graduated in Biomedical Sciences (King’s College, London and Berkeley, University of California) before undertaking post-graduate studies at the London School of Hygiene and Tropical Medicine. She obtained an MSc in Control of Infectious Diseases, before completing a PhD entitled ‘A policy analysis of biological warfare defence and emerging infectious diseases in an international context'."

Bobby Kaura

Seed Investment, EMEA Entrepreneurial Development & International Evolution

Illumina Accelerator

Bobby helped co-launch Illumina Cambridge Accelerator, the second location for Illumina Accelerator, a genomics breakthrough and VC backable company creation engine. In his current role, he looks to grow the life sciences and genomics ecosystem by partnering with entrepreneurs, investors and individuals within the innovation/entrepreneurial ecosystem. His current focus is looking at new models that can support entrepreneurs and start-ups in different geographies. Previously, he was responsible for heading commercial market and business development for Illumina EMEA with a focus on how genomics can enable precision health through the application of next-generation sequencing technologies. He advocates for building ecosystems that support better population and patient outcomes.

Before joining Illumina, he worked in the NHS to deliver sustainable transformation programs and spent several years working in the pharma industry across early research & development, group planning & strategic projects (executive) office and leading the UK value-based medicine and pricing innovation stream.

He is a member of the advisory board at Praesens Foundation (set-up to provide access to health programs, to communities in hard-to-reach regions and resource-limited settings), Expert in Residence at Cambridge Judge Business School & Oxford University Translational Research Office and member of NHS Innovation Accelerator panel. In addition, he advises health, tech and blockchain startups.

Jakub Majcher

Consultant, Business Development

Virdis Group

Jakub has worked in talent acquisition since 2014. He has significant experience across the whole lifecycle of the recruitment process – from marketing and business development, through qualifying roles, resourcing, advertising, interviewing, referencing and offer negotiation.

Jakub has lived in Poland, France, Spain and the UK, and this international experience combined with a strategic approach, eagerness for understanding of client requirements and focus on due diligence, has allowed him to establish a track record of placing the right people in the right roles. Since joining Virdis in 2018, Jakub has focused on engaging and building strong partnerships with new and existing clients, helping them build and grow their companies.

‘Kuba’ is fluent in four languages and has a BA in Modern Languages & International Relations from Nottingham Trent University.

Colin McCall

Partner

Taylor Wessing

Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

Michael McGivern

Senior Membership and Business Development Manager

BIA

Michael is a BSc Biology graduate with four years’ experience in Business Development and Sales roles covering the pharmaceutical and Higher Education sectors. Following University, he worked for a multi-national raw material distributor in the north-west, supplying API’s and excipients to pharmaceutical manufacturers and then moved on to the University of London. Here he managed the tender process for their SaaS products as well as various account management duties for their Not-For-Profit, HE institution and Charity customers.

Having joined the BIA in April 2017, his role is to bring new companies into membership, while developing engagement with current members.

Ross McNaughton

Partner, Cambridge

Taylor Wessing

Ross is a partner in the Corporate Technology team, based in our Cambridge office.
Ross’s practice focuses on helping tech and life sciences companies in all aspects of their growth, capital raising and international expansion. He has extensive experience of a variety of venture financing and public capital raisings, mergers and acquisitions and general corporate advice, with a particular specialism in transactions with a transatlantic component.

Ross has extensive experience of transactions involving the US and was based out of San Francisco, CA in 2018 19. As a result, he has a particular expertise in supporting US investors and companies in their investment into the UK and elsewhere, as well as counselling UK companies looking to take investment from, or exit to, the US. He is an English qualified solicitor and registered foreign legal consultant in California.

Ross is the co author of PLC’s leading article on M&A pricing structures: Pricing Mechanisms: locked box vs completion accounts.

Andrei Nedelea

Associate Director - Life Sciences Practice

Gallagher

Simon Pannett

Director of Market Access & Pricing STrategy

MAP BioPharma

Simon has over 25 years’ experience in market access from a range of pharmaceutical companies including Servier and Janssen (J&J), Medtech (Coloplast), Digital HealthTech (Patients Know Best) and consulting companies (Intraquad). Simon has experience working across a broad range of products and disease areas from chronic disease such as diabetes through to HIV, Vaccines, Oncology and also Medical devices and health technology products. Throughout his career he has developed and implemented market access projects at global, national and local levels, including developing market access strategies, innovative approaches and evidence for global product launches, developing value propositions, HTA strategy and submissions, payer engagement and patient support programmes. Simon has a real passion for helping companies understand the context into which they are launching medicines so that they tailor their value propositions and messaging in ways that resonates with NHS decision makers.

Oliver Pumfrey

Managing Director

FTI Consulting

Oliver Pumfrey manages the Life Sciences Tax team and has over 15 years of experience.

Latterly Oliver worked in industry where he was responsible for all taxes across the EMEA region for a multinational US listed group.

Prior to that, Oliver spent 10 years with PwC, working across a number of tax areas including corporate tax, employment taxes and the tax technical knowledge team.

Oliver supports Life Sciences clients across a range of tax matters including R&D incentive claims for large enterprises and SMEs and related transactional advice and planning. He also advises on the Enterprise Investment Scheme, licensing of intellectual property rights and Patent Box elections in regards to optimal timing and the potential benefits.

Nathalie Rowell

CEO and Founder

Virdis Group

Nathalie brings over 18 years of experience and credibility in hiring international talent for the life science industry. She continues to advise senior executives in many different cultures on how to shape their careers and their organizations. A solid track record of international success has given Nathalie a deep understanding of the life-sciences and a strong empathy with our clients. Her extensive industry knowledge and specialist insight is valued highly, enabling Virdis clients to benchmark realistically, evaluate carefully, and find exactly the right individuals to lead and develop their organisations.

Nathalie created Virdis in 2007 and, since then, has built both a strong team and a broad network of skilled people around the world. Her understanding of life science organisations and her extensive experience make her a credible and well-recognized recruitment partner.

Nathalie read Law at Paris Assas University and worked as lawyer in the field of intellectual property before becoming an entrepreneur and moving to international executive search.

Anya Roy

Head of Cambridge Accelerator

Illumina Accelerator

Anya joined Illumina in January 2020 to lead Illumina Accelerator Cambridge. She has experience as an Entrepreneur, venture capital Investor and as a Banker.

She was previously the founder and CEO of Syrona, a digital health start-up that develops low-cost, non-invasive screening kits for women’s health issues pioneering combination of digital and biological markers. She worked at Goldman Sachs and in life science venture capital at IP Group prior to founding her own company.

She earned a MPhil with a focus in Bioscience from the University of Cambridge in Cambridge, England and currently completing her Executive MBA from Said business school at Oxford University having been conferred the prestigious 30% club scholarship."

Diana Sternfeld

Head of IP

LifeArc

Until she joined LifeArc in 2019, Diana was a patent litigator with particular expertise in biotechnology patents. Her patent career began with the landmark case of Biogen against Medeva, the first biotechnology case to be heard in the House of Lords. She is now Head of Intellectual Property at the medical research charity, LifeArc. She has been an active participant in the BIA for many years and was a member of the Board from 2011 until she resigned in 2021. During that time she was member of the Executive Committee of the Board assisting in the operational oversight of the Association. As well as a qualified solicitor, she is an Associate Member of the Chartered Institute of Patent Attorneys and an accredited mediator.

Laure Storck

Consultant

Virdis Group

Laure is a seasoned executive search consultant, with a solid track record in search strategy and execution of senior level assignments in the life sciences. She has led and trained the research team to high standard of delivery, building long-term, trusted relationships with clients and candidates. Laure joined Virdis in 2010 and is now responsible for many of the client relationships developed over the last decade; and takes overall leadership for business development planning.

Laure has a Master’s Degree in Human Resources from IGS Paris, a Postgraduate Diploma in German from the University of Strasbourg and is qualified as an Accountant (DECF).

Prior to joining the Virdis Group Laure worked in human resources and training within Sanofi and GlaxoSmithKline in France. Laure moved to the UK in 2008 and has helped to build the successful team at Virdis Group.

Clare Terlouw

Head of LifeArc Ventures

LifeArc

Clare is an experienced life sciences corporate finance and investment specialist, with significant expertise in growth funding for innovative life sciences companies in the private and public markets. Clare has been on the BIA board since January 2019 and is now seeking re-election. Clare joined LifeArc in July 2020 as Head of LifeArc Ventures, responsible for developing and implementing a strategy for LifeArc’s investments across the life sciences sector, enhancing LifeArc’s commitment to funding the translation of promising life sciences research. LifeArc’s strategic investments in innovation are a key component of its charitable model, supporting both the ability to create impact for the benefit of patients and aims to contribute to its long-term sustainability.
Clare was recently at FTSE250 listed healthcare investment company Syncona Investment Management, where she was Head of Corporate Development. She also has over 15 years’ experience in healthcare investment banking and was Managing Director and Co-Head of Healthcare and Life Sciences at Numis Securities, specialising in equity capital markets and M&A for London listed companies. Clare is also a Non-Executive Director at the Stevenage Bioscience Catalyst.
Clare has been an enthusiastic supporter of the life sciences sector and understands the opportunities and challenges that funding growing companies in the sector brings. She is currently a member of the BIA Audit Committee and intends to continue in that role.

Adrian Toutoungi

Partner, Cambridge

Taylor Wessing

Adrian is a seasoned IP lawyer who relishes immersing himself in his client’s technology, product roadmap and patent/IP strategy. He is regularly involved in the negotiation and drafting of technology licence agreements and other contracts with a heavy IP element, such as R&D collaborations, joint ventures, grant funding agreements and other commercial arrangements. He also advises on the EC and UK competition law aspects of these agreements, and issues relating to technical standardisation, essential IPR and patent pooling.

Adrian has a wealth of experience in handling the IP aspects of University spin outs, IPOs and other major corporate transactions and disputes, including for FTSE 100 and Fortune 500 corporations. He is also a valued patent litigator, having recently advised on disputes involving pharmaceuticals, somatic cell therapy, semiconductor chip design, inkjet printing technology, digital compression algorithms, LCD flat panel technology, telecoms and pharmaceuticals. He also frequently helps clients with disputes involving confidential information, database rights, trade marks, copyright and designs.

Adrian publishes and speaks regularly on a variety of intellectual property issues.

Richard Turner

Senior Managing Director

FTI Consulting

Richard Turner is a specialist in UK and International Tax leads FTI Consulting’s Life Science Tax team and tax and innovation services encompassing IP planning, R&D incentives and the UK Patent Box.

With over 25 years of experience, Richard is one of the UK’s leading tax specialists in Life Sciences. He regularly provides input to HMRC and HM Treasury for R&D tax incentives, the Patent Box and other tax measures that are pertinent to companies operating in the sector.

His roles outside FTI Consulting include BIA Finance & Treasury Committee, Fiscal lead for the Medicines Manufacturing Industry Partnership.

Latterly, Richard was a Partner at Deloitte within its UK Healthcare and Life Science leadership team working with several global pharmaceutical and medical device companies.

Prior to that, Richard worked as an International Tax Director for PowderJect Pharmaceuticals Plc and Chiron Corporation, spending significant time in the US, Germany and Italy.

Kyriakos Tzafestas

Associate

PharmaVentures

Kyriakos joined PharmaVentures as an Associate. Prior to joining PharmaVentures, Kyriakos was a life sciences consultant working with biotech companies and early-stage technologies on projects encompassing market analysis, competitive intelligence, opportunity assessment, commercialisation roadmaps, patent landscaping, valuations, and business development for research collaborations and licensing opportunities. Kyriakos has also served as the Industry Programme Manager for the Royal Society, overseeing their research translation programme and advising public policy on Research & Innovation.

Before commencing his professional career, Kyriakos completed a Master of Biotechnology (Distinction) at the University of Glasgow and obtained a PhD in Molecular Biology from the University of York.

Helen Wass

Senior Director, European Tax Advisory

FTI Consulting

Helen Wass works exclusively with Life Sciences companies in the Tax team at FTI Consulting. She has over 20 years experience working in finance and tax in - house roles in the pharmaceutical industry.
Prior to joining FTI Consulting, Helen worked at GSK, then latterly at Vernalis plc, a pharmaceutical company with operations in the UK and the US, where she was responsible for all taxes. She has a broad range of in-house experience in UK tax compliance and R&D incentives, as well as VAT, employment tax and share options, transfer pricing and US compliance.

She joined FTI Consulting in 2019, and since joining has worked with a number of clients in the life science sector, providing ongoing assistance with R&D claims and UK tax compliance, as well as specific advice on licensing deals, and other transactions. She focuses on providing pragmatic advice drawing on her experiences in-house.

Helen trained with KPMG and holds a BSc in Biochemistry & Biological Chemistry from the University of Nottingham.

Dr Karolina Zapadka

Head of Babraham Accelerator

Babraham Research Campus

Karolina joined the Babraham Research Campus in 2018 where she co-founded and successfully delivered the Accelerate@Babraham initiative. As part of this, Karolina launched the first life science acceleration programme for early stage ventures combining access to lab space, mentoring from business and scientific experts and access to investors in the Cambridge Cluster.

Karolina’s strong interest in life science entrepreneurship and expediting treatment to patients led her to join the Oxbridge Biotech Roundtable in 2013 where she launched the OneStart competition. She then co-founded and became Chief of Staff at the Global Innovation Forum and IMAGINE IF! accelerator in 2014. This experience gave her strong relationships with various partners regionally, nationally and internationally – including investors, academic leaders and CEO’s of biotech and big pharmaceutical companies.

Karolina has over 7 years experience in building healthcare companies within the Cambridge Cluster. She was pivotal in securing over £7.5 million for a number of British early stage ventures (pre-seed and seed stage) from a stellar syndicate of investors (business angels and VCs). She started her career as a scientist in protein and peptide therapeutics at a leading biopharmaceutical company developing a portfolio of products to enable improved treatments for diabetes care. Karolina completed a PhD in Biophysics at the University of Cambridge and carried out her Postdoctoral work at AstraZeneca.

 

Costs & T&Cs

BIA members:     £30 +VAT
Non-members:   £50 +VAT

By registering to this event you accept our Terms & Conditions

Please note: this event is limited to attendees from start-up companies, entrepreneurs in the life sciences, and invited industry experts.
If you are interested in supporting this event please contact Jane Wall at jwall@bioindustry.org

If you have any questions or problems registering, please contact biaevents@bioindustry.org or to find our more about BIA membership for emerging companies, please click here.

Joining instructions will be sent out to event attendees on 10 May 2021.

Virtual format

The event platform will open on 10 May for networking and attendees will be sent joining instructions on this date. 

We are planning to run this event using an event platform called Swapcard, with sessions hosted on zoom for greater engagement between attendees and speakers.

Please note that:

  • Swapcard can be accessed on a laptop, desktop, mobile or tablet 
  • Swapcard works on all browsers except Internet Explorer
  • It is recommended you attend using a device with a webcam and microphone so that you can video chat with other attendees via the one to one meeting tool 
  • The web app is available on smartphone and computer using the following link: https://app.swapcard.com/
  • The mobile app is available on iPhone and Android. To download it, use the following link: https://www.swapcard.com/app/swapcard
  • You will need to download the Zoom application on either your laptop, desktop, mobile, or tablet to particpate in the sessions.
  • Recordings of the sessions will be available on-demand for two weeks after the event.

Virtual networking reception

The evening networking will take place on a separate platform that offers an engaging virtual venue space that will encourage networking around "tables", which mimics as closely as possible the experience at an in-person event.

What are the technical requirements to attend the virtual networking reception?

  • There is no software installation or download required.
  • Please attend using a laptop or desktop computer with audio and video capabilities (webcam and microphone). 
  • You will need to use one of the supported browsers to have the best user experience: Chrome, Safari, or Firefox.
  • If you want to check the technical requirements in more detail, you can view their checklist here.

If your company has firewalls or browsing restrictions in place, please test your connection and liaise with your IT team in advance to ensure you are able to fully participate in the event.

Event partners

Thank you to our event partners, who are also offering their expertise to attendees through 1-1 meetings. 

 

 

Thank you to our Event Supporters
 

 

BIA Annual Supporters

Register